Novel lipometabolism biomarker for chemotherapy and immunotherapy response in breast cancer
Abstract Emerging proof shows that abnormal lipometabolism affects invasion, metastasis, stemness and tumor microenvironment in carcinoma cells. However, molecular markers related to lipometabolism have not been further established in breast cancer. In addition, numerous studies have been conducted...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-10-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-022-10110-8 |
| _version_ | 1811202752817135616 |
|---|---|
| author | Lei Zhang Risheng She Jianlin Zhu Jin Lu Yuan Gao Wenhua Song Songwang Cai Lu Wang |
| author_facet | Lei Zhang Risheng She Jianlin Zhu Jin Lu Yuan Gao Wenhua Song Songwang Cai Lu Wang |
| author_sort | Lei Zhang |
| collection | DOAJ |
| description | Abstract Emerging proof shows that abnormal lipometabolism affects invasion, metastasis, stemness and tumor microenvironment in carcinoma cells. However, molecular markers related to lipometabolism have not been further established in breast cancer. In addition, numerous studies have been conducted to screen for prognostic features of breast cancer only with RNA sequencing profiles. Currently, there is no comprehensive analysis of multiomics data to extract better biomarkers. Therefore, we have downloaded the transcriptome, single nucleotide mutation and copy number variation dataset for breast cancer from the TCGA database, and constructed a riskScore of twelve genes by LASSO regression analysis. Patients with breast cancer were categorized into high and low risk groups based on the median riskScore. The high-risk group had a worse prognosis than the low-risk group. Next, we have observed the mutated frequencies and the copy number variation frequencies of twelve lipid metabolism related genes LMRGs and analyzed the association of copy number variation and riskScore with OS. Meanwhile, the ESTIMATE and CIBERSORT algorithms assessed tumor immune fraction and degree of immune cell infiltration. In immunotherapy, it is found that high-risk patients have better efficacy in TCIA analysis and the TIDE algorithm. Furthermore, the effectiveness of six common chemotherapy drugs was estimated. At last, high-risk patients were estimated to be sensitive to six chemotherapeutic agents and six small molecule drug candidates. Together, LMRGs could be utilized as a de novo tumor biomarker to anticipate better the prognosis of breast cancer patients and the therapeutic efficacy of immunotherapy and chemotherapy. |
| first_indexed | 2024-04-12T02:43:48Z |
| format | Article |
| id | doaj.art-0947e531812b473aa7849c8aea432062 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-04-12T02:43:48Z |
| publishDate | 2022-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-0947e531812b473aa7849c8aea4320622022-12-22T03:51:13ZengBMCBMC Cancer1471-24072022-10-0122111310.1186/s12885-022-10110-8Novel lipometabolism biomarker for chemotherapy and immunotherapy response in breast cancerLei Zhang0Risheng She1Jianlin Zhu2Jin Lu3Yuan Gao4Wenhua Song5Songwang Cai6Lu Wang7Department of Gastrointestinal Surgery, the First Affiliated Hospital of Jinan UniversityDepartment of Emergency, Dongguan People’s HospitalDepartment of Gastrointestinal Surgery, the First Affiliated Hospital of Jinan UniversityLaboratory of Computational Medicine and Intelligent Health, Bengbu Medical CollegeDepartment of Medical Ultrasound, the Second Affiliated Hospital of Bengbu Medical CollegeDepartment of Oncology Surgery, the Second Affiliated Hospital of Bengbu Medical CollegeDepartment of Thoracic Surgery, The First Affiliated Hospital of Jinan UniversityDepartment of Gastrointestinal Surgery, the First Affiliated Hospital of Jinan UniversityAbstract Emerging proof shows that abnormal lipometabolism affects invasion, metastasis, stemness and tumor microenvironment in carcinoma cells. However, molecular markers related to lipometabolism have not been further established in breast cancer. In addition, numerous studies have been conducted to screen for prognostic features of breast cancer only with RNA sequencing profiles. Currently, there is no comprehensive analysis of multiomics data to extract better biomarkers. Therefore, we have downloaded the transcriptome, single nucleotide mutation and copy number variation dataset for breast cancer from the TCGA database, and constructed a riskScore of twelve genes by LASSO regression analysis. Patients with breast cancer were categorized into high and low risk groups based on the median riskScore. The high-risk group had a worse prognosis than the low-risk group. Next, we have observed the mutated frequencies and the copy number variation frequencies of twelve lipid metabolism related genes LMRGs and analyzed the association of copy number variation and riskScore with OS. Meanwhile, the ESTIMATE and CIBERSORT algorithms assessed tumor immune fraction and degree of immune cell infiltration. In immunotherapy, it is found that high-risk patients have better efficacy in TCIA analysis and the TIDE algorithm. Furthermore, the effectiveness of six common chemotherapy drugs was estimated. At last, high-risk patients were estimated to be sensitive to six chemotherapeutic agents and six small molecule drug candidates. Together, LMRGs could be utilized as a de novo tumor biomarker to anticipate better the prognosis of breast cancer patients and the therapeutic efficacy of immunotherapy and chemotherapy.https://doi.org/10.1186/s12885-022-10110-8LipometabolismTumor microenvironmentImmunotherapyChemotherapyBreast cancer |
| spellingShingle | Lei Zhang Risheng She Jianlin Zhu Jin Lu Yuan Gao Wenhua Song Songwang Cai Lu Wang Novel lipometabolism biomarker for chemotherapy and immunotherapy response in breast cancer BMC Cancer Lipometabolism Tumor microenvironment Immunotherapy Chemotherapy Breast cancer |
| title | Novel lipometabolism biomarker for chemotherapy and immunotherapy response in breast cancer |
| title_full | Novel lipometabolism biomarker for chemotherapy and immunotherapy response in breast cancer |
| title_fullStr | Novel lipometabolism biomarker for chemotherapy and immunotherapy response in breast cancer |
| title_full_unstemmed | Novel lipometabolism biomarker for chemotherapy and immunotherapy response in breast cancer |
| title_short | Novel lipometabolism biomarker for chemotherapy and immunotherapy response in breast cancer |
| title_sort | novel lipometabolism biomarker for chemotherapy and immunotherapy response in breast cancer |
| topic | Lipometabolism Tumor microenvironment Immunotherapy Chemotherapy Breast cancer |
| url | https://doi.org/10.1186/s12885-022-10110-8 |
| work_keys_str_mv | AT leizhang novellipometabolismbiomarkerforchemotherapyandimmunotherapyresponseinbreastcancer AT rishengshe novellipometabolismbiomarkerforchemotherapyandimmunotherapyresponseinbreastcancer AT jianlinzhu novellipometabolismbiomarkerforchemotherapyandimmunotherapyresponseinbreastcancer AT jinlu novellipometabolismbiomarkerforchemotherapyandimmunotherapyresponseinbreastcancer AT yuangao novellipometabolismbiomarkerforchemotherapyandimmunotherapyresponseinbreastcancer AT wenhuasong novellipometabolismbiomarkerforchemotherapyandimmunotherapyresponseinbreastcancer AT songwangcai novellipometabolismbiomarkerforchemotherapyandimmunotherapyresponseinbreastcancer AT luwang novellipometabolismbiomarkerforchemotherapyandimmunotherapyresponseinbreastcancer |